肺癌篩檢市場規模、佔有率和成長分析（按癌症類型、診斷方法、最終用戶和地區分類）—2026-2033年產業預測

2024 年全球肺癌篩檢市場規模為 38.2 億美元，預計將從 2025 年的 41.7 億美元成長到 2033 年的 83.6 億美元，預計在預測期（2026-2033 年）內將以 9.1% 的複合年成長率。

受篩檢技術進步和全球吸菸率上升的推動，全球肺癌篩檢市場正經歷強勁成長。由於許多人仍然每天吸煙，肺癌發病率的不斷上升推動了對有效篩檢方案的需求。醫療專業人員對低劑量電腦斷層掃描（CT）的廣泛應用進一步促進了這項需求。此外，人們對創新且經濟實惠的篩檢方法的認知不斷提高，尤其是在開發中國家，也促進了市場擴張。主要參與者之間的合作策略，例如旨在提高公眾意識的夥伴關係，也發揮著重要作用。然而，為了實現永續成長，需要透過技術創新和教育宣傳活動來解決高昂的篩檢成本和對輻射暴露的擔憂等挑戰。

推動全球肺癌篩檢市場發展的因素

肺癌是全球癌症死亡的首要原因，其發生率的不斷上升是推動肺癌篩檢政策實施的關鍵因素。病例數的增加，尤其是在開發中國家，凸顯了有效早期檢測策略的迫切性。隨著人們對篩檢益處的認知不斷提高，衛生系統也逐漸認知到採取積極措施在早期發現和治療肺癌的重要性。這種對篩檢的日益重視不僅旨在降低死亡率，也強調了更廣泛的預防保健的重要性。

全球肺癌篩檢市場面臨的限制因素

全球肺癌篩檢市場面臨許多挑戰，其中低劑量電腦斷層掃描（LDCT）可能出現偽陽性結果。這些假陽性結果可能導致患者需要進行額外的檢查，造成不必要的焦慮，增加醫療成本，並可能增加不必要的醫療程序帶來的併發症風險。此外，過度診斷問題也日益凸顯，即患者被發現存在一些不太可能構成威脅的肺結節，導致過度治療和不必要的干涉。這些因素加劇了人們對肺癌篩檢的猶豫和懷疑，最終阻礙了市場成長和普及。

全球肺癌篩檢市場趨勢

全球肺癌篩檢市場正經歷顯著的轉變，朝著根據個別風險狀況量身定做的個人化篩檢方法發展。透過整合吸菸史、職業暴露和遺傳易感性等因素，醫療機構正在提高篩檢計畫的準確性和有效性。這一趨勢著重於利用風險分層演算法來識別和優先篩選高風險族群，從而最佳化資源分配並提高早期檢出率。隨著人們對肺癌的認知不斷提高以及推動個人化醫療的技術進步，這種客製化策略有望在全球肺癌篩檢通訊協定的變革中發揮關鍵作用。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 技術進步
• 監管環境
• 專利分析

全球肺癌篩檢市場規模（按癌症類型和複合年成長率分類）（2026-2033 年）

• 非小細胞肺癌（NSCLC）
• 小細胞肺癌

全球肺癌篩檢市場規模（按診斷方法和複合年成長率分類）（2026-2033 年）

• 低劑量螺旋電腦斷層掃描
• 胸部X光片

全球肺癌篩檢市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院和診所
• 診斷中心

全球肺癌篩檢市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• General Electric Company（USA）
• Koninklijke Philips NV（Netherlands）
• Siemens Healthineers（Germany）
• Canon Medical Systems Corporation（Japan）
• FUJIFILM Holdings Corporation（Japan）
• Medtronic（USA）
• Nuance Communications, Inc.（USA）
• Eon（USA）
• Volpara Health Limited（New Zealand）
• Hitachi, Ltd.（Japan）
• Toshiba Corporation（Japan）
• Hologic, Inc.（USA）
• Agfa-Gevaert Group（Belgium）
• Carestream Health（USA）
• Mindray Medical International Limited（China）
• Esaote SpA（Italy）
• Shimadzu Corporation（Japan）
• ViewRay, Inc.（USA）

結論與建議

Global Lung Cancer Screening Market size was valued at USD 3.82 Billion in 2024 and is poised to grow from USD 4.17 Billion in 2025 to USD 8.36 Billion by 2033, growing at a CAGR of 9.1% during the forecast period (2026-2033).

The global lung cancer screening market is experiencing robust growth, propelled by advancements in screening technologies and the rising rates of tobacco use worldwide. With significant numbers of individuals routinely engaging in tobacco consumption, the need for effective screening solutions has intensified due to the increasing incidence of lung cancer. The widespread adoption of low-dose computed tomography (CT) among healthcare professionals further fuels this demand. Additionally, heightened awareness of innovative and affordable screening methods, especially in developing nations, contributes to market expansion. Collaborative strategies among key players, such as partnerships aimed at increasing public awareness, also play a pivotal role. Nonetheless, challenges such as high screening costs and radiation exposure concerns must be addressed through technological advancements and educational initiatives for sustainable growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Lung Cancer Screening market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Lung Cancer Screening Market Segments Analysis

Global Lung Cancer Screening Market is segmented by Cancer Type, Diagnosis Type, End-user and region. Based on Cancer Type, the market is segmented into Non-small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer. Based on Diagnosis Type, the market is segmented into Low Dose Spiral CT Scan and Chest X-ray. Based on End-user, the market is segmented into Hospitals & Clinics and Diagnostic Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Lung Cancer Screening Market

The increasing prevalence of lung cancer, a major contributor to cancer mortality globally, serves as a crucial catalyst for the implementation of lung cancer screening initiatives. The uptick in cases, especially within developing nations, highlights the urgent need for effective early detection strategies. As awareness about the benefits of screening continues to grow, healthcare systems are recognizing the importance of proactive measures to identify and tackle lung cancer at its nascent stages. This heightened focus on screening not only aims to reduce mortality rates but also emphasizes the importance of preventive healthcare on a broader scale.

Restraints in the Global Lung Cancer Screening Market

The global lung cancer screening market faces significant challenges due to the potential for false-positive results stemming from low-dose computed tomography (LDCT). These false positives can necessitate further examinations, which may induce unwarranted anxiety in patients, incur extra expenses, and raise the risk of complications associated with unnecessary medical procedures. Additionally, the issue of overdiagnosis arises when patients are identified with lung nodules that are unlikely to pose any threat, resulting in overtreatment and unwarranted interventions. These factors contribute to hesitancy and skepticism surrounding lung cancer screening, ultimately hindering market growth and adoption.

Market Trends of the Global Lung Cancer Screening Market

The Global Lung Cancer Screening market is experiencing a notable shift towards personalized screening approaches that cater to individual risk profiles. By integrating factors such as smoking history, occupational exposures, and genetic predispositions, healthcare providers are enhancing the precision and effectiveness of screening programs. This trend emphasizes the use of risk stratification algorithms to identify and prioritize high-risk populations, thereby optimizing resource allocation and improving early detection rates. As awareness of lung cancer grows and technological advancements facilitate personalized medicine, this tailored strategy is expected to play a crucial role in transforming lung cancer screening protocols worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Technology Advancement
• Regulatory Landscape
• Patent Analysis

Global Lung Cancer Screening Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Non-small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer

Global Lung Cancer Screening Market Size by Diagnosis Type & CAGR (2026-2033)

• Market Overview
• Low Dose Spiral CT Scan
• Chest X-ray

Global Lung Cancer Screening Market Size by End-user & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Diagnostic Centers

Global Lung Cancer Screening Market Size & CAGR (2026-2033)

• North America (Cancer Type, Diagnosis Type, End-user)
  • US
  • Canada
• Europe (Cancer Type, Diagnosis Type, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Cancer Type, Diagnosis Type, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Cancer Type, Diagnosis Type, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Cancer Type, Diagnosis Type, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• General Electric Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Koninklijke Philips N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Canon Medical Systems Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FUJIFILM Holdings Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nuance Communications, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eon (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Volpara Health Limited (New Zealand)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hitachi, Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Toshiba Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agfa-Gevaert Group (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Carestream Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mindray Medical International Limited (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Esaote S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shimadzu Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ViewRay, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations